SCHEMBL8469252

SCHEMBL8469252

CC(C)(C)OC(=O)N(CC(=O)O)c1ccc(CO)cc1

nearest known ligand 0.42

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.42
PPARA Q07869 1/20 0.42
MLYCD O95822 2/20 0.37
GPR119 Q8TDV5 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4840303 0.88 NR1H4 (0.45) MLYCD
SCHEMBL11090974 0.87 NR1H2 (0.38) MLYCD
SCHEMBL895556 0.85 MLYCD (0.39) MLYCD
SCHEMBL4840795 0.85 PPARG (0.41) PPARGPPARAMLYCDGPR119
SCHEMBL219603 0.84 SMN1; SMN2 (0.49) MLYCD
SCHEMBL2929114 0.84 MLYCD (0.38) MLYCD
SCHEMBL3375082 0.84 MLYCD (0.38) MLYCD
SCHEMBL266144 0.84 MT-CO2 (0.46) PPARAMLYCD
SCHEMBL3349318 0.84 MLYCD (0.41) MLYCD
SCHEMBL11648528 0.84 MLYCD (0.38) MLYCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0871436-A4 USE OF Stat 6 SH2 DOMAIN SPECIFIC COMPOUNDS TO TREAT ALLERGIC REACTIONS SMITHKLINE BEECHAM CORP (US) 1999-10-20 EP disclosed
EP-0809490-A4 USE OF LCK SH2 SPECIFIC COMPOUNDS TO TREAT AUTOIMMUNE DISEASES AND ALLOGRAFT REJECTION SMITHKLINE BEECHAM CORP (US) 1999-10-20 EP disclosed
EP-0835104-A4 USE OF STAT 5 SH2 DOMAIN SPECIFIC COMPOUNDS TO ENHANCE ERYTHROPOIESIS SMITHKLINE BEECHAM CORP (US) 1999-10-20 EP disclosed
EP-0871436-A1 USE OF Stat 6 SH2 DOMAIN SPECIFIC COMPOUNDS TO TREAT ALLERGIC REACTIONS SMITHKLINE BEECHAM CORPORATION (US) 1998-10-21 EP disclosed
CN-1179713-A Use of LCK SH2 specific compounds to treat autoimmune diseases and allograft rejection SMITHKLINE BEECHAM CORP (US) 1998-04-22 CN disclosed
EP-0835104-A1 USE OF STAT 5 SH2 DOMAIN SPECIFIC COMPOUNDS TO ENHANCE ERYTHROPOIESIS SMITHKLINE BEECHAM CORPORATION (US) 1998-04-15 EP disclosed
EP-0809490-A1 USE OF LCK SH2 SPECIFIC COMPOUNDS TO TREAT AUTOIMMUNE DISEASES AND ALLOGRAFT REJECTION SMITHKLINE BEECHAM CORPORATION (US) 1997-12-03 EP disclosed
WO-1997002024-A1 USE OF STAT 5 SH2 DOMAIN SPECIFIC COMPOUNDS TO ENHANCE ERYTHROPOIESIS SMITHKLINE BEECHAM CORPORATION (US) 1997-01-23 WO disclosed
WO-1997002023-A1 USE OF Stat 6 SH2 DOMAIN SPECIFIC COMPOUNDS TO TREAT ALLERGIC REACTIONS SMITHKLINE BEECHAM CORPORATION (US) 1997-01-23 WO disclosed
EP-0728482-A2 Use of hcp specific compounds to enhance erythropoiesis SMITHKLINE BEECHAM CORPORATION (US) 1996-08-28 EP disclosed
EP-0727211-A1 Use of src SH2 specific compounds to treat a bone resorption disease SMITHKLINE BEECHAM CORPORATION (US) 1996-08-21 EP disclosed
WO-1996024343-A1 USE OF LCK SH2 SPECIFIC COMPOUNDS TO TREAT AUTOIMMUNE DISEASES AND ALLOGRAFT REJECTION SMITHKLINE BEECHAM CORPORATION (US) 1996-08-15 WO disclosed
US-4297489-A CEPHALOSPORINS BRISTOL-MYERS COMPANY (US) 1981-10-27 US disclosed
US-4018759-A BACTERICIDES SMITHKLINE CORPORATION (US) 1977-04-19 US disclosed
US-3987041-A P-HYDROXYMETHYLPHENYLACETAMIDOCEPHALOSPORINS SMITHKLINE CORPORATION (US) 1976-10-19 US disclosed
US-3972919-A CHEMICAL INTERMEDIATE FOR ANTIBIOTICS SMITHKLINE CORPORATION (US) 1976-08-03 US disclosed
US-3962230-A BACTERICIDES SMITHKLINE & FRENCH LABORATORIES, INC. (US) 1976-06-08 US disclosed
US-3957768-A BACTERICIDES SMITHKLINE CORPORATION (US) 1976-05-18 US disclosed
US-3946005-A BACTERICIDES SMITHKLINE CORPORATION (US) 1976-03-23 US disclosed
US-3943129-A BACTERICIDE SMITHKLINE CORPORATION (US) 1976-03-09 US disclosed